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Background: Hepatobiliary cystadenocarcinoma is a rare epithelial malignant neoplasm of the liver or extrahepatic
bile ducts. Early diagnosis of hepatobiliary cystadenocarcinoma is difficult because of its asymptomatic features
and rarity. Moreover, the molecular pathogenesis of hepatobiliary cystadenocarcinoma remains unclear. Herein,
we described a case of hepatobiliary cystadenocarcinoma in female with chronic hepatitis B and repeated
hepatolithiasis.
Case presentation: A 65-year-old woman with medical history of latent hepatitis B virus infection, repeated
choledocholisthiasis, and cholecystitis was admitted due to a heterogeneous cystic mass (5.6 cm × 4 cm) shown
on abdominal ultrasonography during regular physical checkup. The patient complained about irregular bowel
movements with intermittent diarrhea for two months before presentation. Computed tomography (CT) disclosed
a multiloculated cystic lesion in the left hepatic lobe with the presence of intraductal stones and dilatation of
intrahepatic ducts. Histological results obtained from left lobectomy specimens showed hepatobiliary cystadenocarcinoma
without accompanied mesenchymal stroma.
Conclusion: Notably, hepatobiliary cystadenocarcinoma without mesenchymal stroma seldom occurs in women and
is usually associated with poor prognosis. We present the rare findings in this patient and suggest that chronic
inflammatory insults in the intrahepatic bile ducts might shed light on the cystadenocarcinogenesis.
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Hepatobiliary cystadenocarcinoma is a rare cystic neo-
plasm that predominantly occurs in the middle-aged
women. Its early detection is challenging because of va-
ried clinical features [1]. The tumor may originate from
pre-existing cystadenoma or from other benign cystic le-
sions. However, it can also develop “de novo” from the
biliary epithelium or peribiliary glands [2]. The two sub-
groups, cystadenocarcinoma with mesenchymal stroma
and without stroma may yield different clinical outcomes
[3]. The presence of mesenchymal stroma that resembles
ovarian stroma (OS) suggests the possible etiology du-
ring embryonic development and its female preponde-
rance [4]. In the context of OS, cystadenoma is usually* Correspondence: albreb@ms28.hinet.net
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unless otherwise stated.the prerequisite for cystadenocarcinoma. On the con-
trary, the mechanisms of cystadenocarcinogenesis for
subtype without OS remains unclear. Chronic inflamma-
tion stimulated by hepatolithiasis may play a significant
role in driving the malignant transformation of cholan-
giocarcinoma [5] and intraductal papillary neoplasia of
the liver [6]. We suspect that this may also associate with
the carcinogenesis of hepatobiliary cystadenocarcinoma.
We report here on a case of a hepatobiliary cystadenocar-
cinoma without mesenchymal stroma and discuss the
involvement of chronic inflammatory assailants caused
by hepatholithiasis, chronic HBV infection, and surgical
intervention.
Case presentation
A 65-year-old woman was admitted to our hospital for
surgical intervention due to one liver tumor identified on
the abdominal ultrasonography during regular follow-up. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported to have irregular bowel movement with loose stool
passage and weight gain for about two months. She expe-
rienced no abdominal pain, fullness or vomiting. When
tracing her past history, the patient had undergone chole-
cystectomy for cholecystitis and received two times of
laparotomy in regard to repeated choledocholisthiasis
caused by hepatolithiasis about 30 and 20 years ago, re-
spectively. Besides, four of the patient’s seven siblings were
diagnosed with hepatitis B-related hepatocellular carcin-
oma, which had contributed to their death and severe
morbidity.
The physical examination was unremarkable. There
was no abdominal tenderness, rebounding tenderness
and abnormal bowel sounds. Murphy’s sign was also
negative. Laboratory studies on admission yield normal
blood biochemistry and mild thrombocytopenia (127000
per cubic millimeter). The liver function test showed
normal results (AST = 19 U/L, ALT = 16 U/L). No pro-
longed prothrombin times or partial-thromboplastin
times was found. Direct and total bilirubin were not ele-
vated. Enzymes such as gamma-glutamyl transferase or
alkaline phosphatase were within normal ranges. The
urinalysis was normal, without dark or tea-colored urine.
The levels of tumor markers such as AFP, CEA, CA125
and CA19-9 were all within normal limits.
Ultrasonography (Figure 1) disclosed a heterogeneous
cystic lesion about 7.6 cm × 5.5 cm over the lateral seg-
ment of left hepatic lobe with dilatation of intrahepatic
ducts. Computed tomography (CT) of abdomen demon-
strated multiloculated cystic tumor with internal septa
in the left lobe of the liver (Figure 2). In addition, non-
calcified stones were found in dilated intrahepatic bile
duct and common bile duct. Under the impression of
cholangiocarcinoma, left lobectomy of liver and choledo-
cholithotomy were performed. The cystic tumor wasFigure 1 Abdominal ultrasonography. Abdominal ultrasonography
(US) showed a multiloculated cystic mass over the lateral segment of
left hepatic lobe.smoothly removed with clear margin. Grossly, the resected
tumor demonstrated multi-cystic and ill-defined appear-
ance beneath the liver capsule (Figure 3). All sections were
embedded and examined. Microscopically, a cyst lined by
proliferating epithelia composed of papillary proliferation
of dysplastic cells with mucin hypersecretion was identi-
fied (Figure 4A). It was supported by fibromuscular struc-
ture where ovary-like stroma was not seen. Furthermore,
malignant picture with deregulated growth pattern and
perineural invasion was demonstrated in some regions
(Figure 4B). The cystic tumor was finally diagnosed as a
hepatobiliary cystadenocarcinoma without mesenchymal
stroma (pT1N0M0).
After total resection of the tumor, the patient was hos-
pitalized for several days. She had no fever, no distention
and other morbidities before discharge. Her incision had
healed well 3 weeks after discharge. She showed no ad-
verse event related to hepatobiliary disease or the sur-
gery. The follow up MRI three years after operation
confirmed no recurrence of malignancy.
Discussion
Hepatobiliary cystadenocarcinoma is a rare cystic neo-
plasm that usually presents as a multilocular cystic mass
with internal septations, nodules, and irregular, thick-
ened cyst wall [1,7,8]. It may occur at any age with fe-
males affected more than males. Though the exact
etiology remains uncertain, it has been proposed that
the majority of these tumors come from a pre-existing
cystadenoma or benign bile duct cysts [2,9]. In addition,
some studies suggested that the cystic adenocarcinomas
are the cystic variants of cholangiocarcinoma with shared
biliary phenotypes [1]. This makes the clinicopathological
features more varied than its counterpart, cystadenomas
alone. The cystic tumors in females that frequently present
ovarian-like stroma (OS) are not observed in male cases
[1]. It may be due to the proximity between liver and
gonads during embryonic development and tissue migra-
tion [4], which can explain why cystadenoma and cystade-
nocarcinoma with OS exclusively occurs in women. In
addition, the expression of estrogen and progesterone re-
ceptors in the stromal cells also demonstrates the female
predominance in the disease series [10]. CA 19–9, a
marker that is elevated in gastrointestinal cancer and bile
duct diseases, has been previously reported to be elevated
in hepatobiliary cystadenocarcinoma with OS [11] but
within normal range in its counterpart without OS [12].
This is manifested in the present case, which further im-
plies the difference between these two subtypes. Clinically,
the presence of mesenchymal stroma that resembles OS
indicates a relatively indolent course and a better progno-
sis [3]. However, the malignant potential of this subtype
engender the necessity for total resection. On the contrary,
cystadenocarcinomas without mesenchymal stroma occur
Figure 2 Computed tomography of the liver and bile duct. (A) Computed tomography (CT) disclosed multiloculated cystic lesion with
internal septa (arrow). (B) Gallbladder stone was identified (arrow). (C) After the administration of contrast medium, there was enhancement
delineating the contour of the cystic tumor (arrow). (D) The cystic lesion extended to the lateral division of the left hepatic lobe (arrow).
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studies revealed the survival rate of cystadenocarcinomas
without OS is not more than 50% [1,2]. In our case, how-
ever, the patient who presents hepatobiliary cystadenocar-
cinoma without OS remains in healthy status three years
after surgery.Figure 3 Gross section of the cystic tumor. The resected mass showed
distance beneath the liver capsule.There is currently little evidence describing the genesis
of cystadenocarcinoma without OS. More clinical and
pathological studies are required to determine whether it
is generated directly from biliary epithelium or from other
pre-malignant structures. One possible mechanism of the
initial cystic formation comes from the hyperplasia ofsolitary, multi-cystic and ill-defined appearance with about 0.1 cm of
Figure 4 Pathological findings from the resected lesion. (A) Photograph of the pathologic specimen shows well-differentiated biliary
cystadenocarcinoma characterized by columnar cells arranged in papillary structures (original magnification × 100). Note that there is no ovarian
stroma present. (B) Perineural invasion of the tumor cells is observed in some parts of the tumor (hematoxylin & eosin staining, original magnification × 200).
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trahepatic ducts, the neck of the gallbladder and the larger
intrahepatic bile ducts [13,14]. These glands are proposed
to serve as source of stem cells for biliary epithelia regen-
eration under normal condition and in response to injury
[14]. Therefore, it is reasonable to deduce that patho-
logical insults to these glands may instigate a variety of
disorders including cancer. In support of this, hepatobili-
ary diseases such as cirrhosis, cholangitis and hepatolithia-
sis are correlated with the hyperplasia of peribiliary glands
[1,5,15]. In the present case, multiple insults including sur-
geries [16] due to hepatolithiasis, chronic HBV infection,
and IHD stones may synergistically irritate peribiliary
glands thereby causing progressively pathological changes
and poses risk for malignant changes. In recent years, an
entity named intraductal papillary mucinous neoplasms
(IPMN) has been recognized as a unique neoplasm arising
from intrahepatic biliary tree [17]. It is characterized by
solitary and diffuse growth of biliary epithelia into the bile
ducts with a papillary pattern. Hepatholithiasis has been
suggested to initiate the genesis of IPMN [18]. Chen et al.
[6] reported that chronic inflammation in the context of
hepatolithiasis causes papillary growth of the biliary epi-
thelia with subsequent metaplasia and invasive carcinoma.
Intrahepatic duct stone and intracystic stone formation
has been reported to involve in biliary cystadenoma or
cystadenocarcinoma [19,20]. Importantly, Tseng reported
a case of biliary cystadenocarcinoma featured by hepatho-
lithiasis and bilateral IHD and CBD stones, which might
also contribute to a microenvironment of chronic inflam-
mation [21]. Collectively, these findings converge on the
conclusion that chronic stimulation of bile materials and
calculi may exert negative influence and thereby cause a
variety of hepatobiliary disorders.
In addition to the presence of calculi in hepatolithiasis,
cholestasis is the common phenomenon of cirrhosis, chol-
angitis and bile duct cysts. To prove the effect of cholesta-
sis on the biliary epithelium, Yang and colleagues [22]induced cholestasis in mouse with chemicals such as car-
bon tetrachloride or dimethylnitrosamine (DMN) and bile
duct ligation (BDL). These approaches accelerated pro-
gression of cholangiocarcinoma through down-regulation
of miR-34a and let-7a as well as up-regulation of Lin-28B.
Of particular note, the up-regulation of Lin-28B is associ-
ated with the development of cystic hyperplasia of intrahe-
patic bile ducts. Moreover, atypical cystic hyperplasia was
induced by cholestasis in the progression of cholangiocar-
cinoma. Taken together, the correlation between the cystic
variant of cholangiocarcinoma and cystadenocarcinoma
seems to lie in the cholestasis-mediated cystic formation.
The authors suggest that cystadenocarcinoma could be
caused by cholestasis based on the similar mechanisms.
To avoid development of biliary tract malignancies
due to surgical intervention, anatomic hepatectomy [23]
and laparoscopic right hemihepatectomy [24] could be
performed to treat hepatolithiasis.
Conclusion
In conclusion, we strongly suspect that hepatolithiasis and
other inflammatory changes contribute to the formation of
the patient’s hepatobiliary cystadenocarcinoma, probably
through hyperplasia and neoplasia of peribiliary glands and
biliary epithelia. It is a possible etiology other than benign
cystic lesion or ectopic ovarian tissue during embryonic de-
velopment, and the absence of ovarian stroma also lowers
the possibility of tumorigenesis from pre-existing cystade-
noma. Furthermore, since the absence of OS has poorer
clinical outcomes, early detection and complete resection
of this tumor are the key factors for achieving cure. Regular
ultrasonography checkup is warranted for patient with evi-
dence of hepatholithiasis and associated dilatation of intra-
hepatic ducts for early diagnosis of this malignant disease.
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